Bu məqalə qaralama halındadır Lütfən məqaləni ümumvikipediya və redaktə qaydalarına uyğun şəkildə tərtib edin əgər mümkü

ComiRNAty brendi altında satılanPfizer–BioNTech COVID-19 peyvəndi (INN: tozinaran), Almaniyanın BioNTech biotexnologiya şirkəti tərəfindən hazırlanmış və onun hazırlanmasında klinik sınaqlar, logistika və istehsal dəstəyi üçün Amerika şirkəti Pfizer ilə əməkdaşlıq edən mRNT əsaslı COVID-19 peyvəndidir. Peyvənd yolu ilə verilir. O, lipid nanohissəcikləri ilə əhatə olunmuş SARS-CoV-2-nin tam uzunluqlu sünbül zülalının mutasiya edilmiş formasını kodlayan nukleozidlə dəyişdirilmiş mRNT-dən (modRNT) ibarətdir. İlkin tövsiyədə peyvəndin 21 gün ara ilə iki dozada verilməli olduğu bildirilmişdi, lakin sonradan bu interval ABŞ-da 42 günə, Kanadada isə dörd aya qədər uzadıldı.

ABŞ bazarı üçün Pfizer–BioNTech COVID‑19 peyvəndi flakonu

İstinadlar

"ComiRNTty EPAR"^{[ölü keçid]}. European Medicines Agency (EMA). Retrieved 24 October 2021.
"FDA Approves First COVID-19 Vaccine" (Press release). U.S. Food and Drug Administration (FDA). 23 August 2021. from the original on 23 August 2021. Retrieved 23 August 2021.
Browne R (11 November 2020). "What you need to know about BioNTech – the European company behind Pfizer's Covid-19 vaccine". CNBC. from the original on 4 March 2021. Retrieved 14 January 2021.
Thomas K, Gelles D, Zimmer C (9 November 2020). "Pfizer's early data shows vaccine is more than 90% effective". The New York Times. from the original on 23 November 2020. Retrieved 9 November 2020.
Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. (October 2020). "Safety and Immunogenicity of Two RNT-Based Covid-19 Vaccine Candidates". The New England JouRNTl of Medicine. 383 (25): 2439–50. doi:10.1056/NEJMoa2027906. PMC 7583697. PMID 33053279.
"Pfizer–BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older" 2021-03-02 at the Wayback Machine (PDF). U.S. Centers for Disease Control and Prevention (CDC). 28 September 2021. Retrieved 24 October 2021.
"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNT Vaccine Candidates Against COVID-19 in Healthy Individuals". ClinicalTrials.gov. 30 April 2020. from the original on 11 October 2020. Retrieved 5 August 2021.
Palca J (9 November 2020). "Pfizer says experimental COVID-19 vaccine is more than 90% effective". NPR.org. NPR. from the original on 9 November 2020. Retrieved 9 November 2020.
Herper M (9 November 2020). "Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate". Stat News. from the original on 9 November 2020. Retrieved 9 November 2020.
Ellis R. "CDC: Gap Between Vaccine Doses Could Be 6 Weeks". WebMD. from the original on 4 may 2021. Retrieved 8 July 2021.
"Canada vaccine panel recommends 4 months between COVID doses". ABC News. 4 March 2021. from the original on 26 July 2021. Retrieved 9 July 2021.
Public Health Agency of Canada (2 July 2021). Recommendations on the use of COVID-19 vaccines (PDF). Health Canada (Report). (PDF) from the original on 23 June 2021. Retrieved 9 July 2021.

[1] "ComiRNTty EPAR"^{[ölü keçid]}. European Medicines Agency (EMA). Retrieved 24 October 2021.

[2] "FDA Approves First COVID-19 Vaccine" (Press release). U.S. Food and Drug Administration (FDA). 23 August 2021. from the original on 23 August 2021. Retrieved 23 August 2021.

[3] Browne R (11 November 2020). "What you need to know about BioNTech – the European company behind Pfizer's Covid-19 vaccine". CNBC. from the original on 4 March 2021. Retrieved 14 January 2021.

[4] Thomas K, Gelles D, Zimmer C (9 November 2020). "Pfizer's early data shows vaccine is more than 90% effective". The New York Times. from the original on 23 November 2020. Retrieved 9 November 2020.

[5] Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. (October 2020). "Safety and Immunogenicity of Two RNT-Based Covid-19 Vaccine Candidates". The New England JouRNTl of Medicine. 383 (25): 2439–50. doi:10.1056/NEJMoa2027906. PMC 7583697. PMID 33053279.

[:0-6] "Pfizer–BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older" 2021-03-02 at the Wayback Machine (PDF). U.S. Centers for Disease Control and Prevention (CDC). 28 September 2021. Retrieved 24 October 2021.

[7] "Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNT Vaccine Candidates Against COVID-19 in Healthy Individuals". ClinicalTrials.gov. 30 April 2020. from the original on 11 October 2020. Retrieved 5 August 2021.

[8] Palca J (9 November 2020). "Pfizer says experimental COVID-19 vaccine is more than 90% effective". NPR.org. NPR. from the original on 9 November 2020. Retrieved 9 November 2020.

[9] Herper M (9 November 2020). "Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate". Stat News. from the original on 9 November 2020. Retrieved 9 November 2020.

[10] Ellis R. "CDC: Gap Between Vaccine Doses Could Be 6 Weeks". WebMD. from the original on 4 may 2021. Retrieved 8 July 2021.

[11] "Canada vaccine panel recommends 4 months between COVID doses". ABC News. 4 March 2021. from the original on 26 July 2021. Retrieved 9 July 2021.

[12] Public Health Agency of Canada (2 July 2021). Recommendations on the use of COVID-19 vaccines (PDF). Health Canada (Report). (PDF) from the original on 23 June 2021. Retrieved 9 July 2021.